IP Due Diligence: Being Prepared When It Matters Most

For a life sciences startup, few moments are more consequential than when a serious investor, strategic partner, or potential acquirer decides to take a close look under the hood. That process — due diligence — is the structured investigation that any sophisticated outside party will conduct before committing capital, entering a significant agreement, or completing an acquisition. While due diligence covers many aspects of a company’s affairs, intellectual property occupies a central place in the life sciences context, often representing the majority of the company’s enterprise value. A startup that has built a strong IP portfolio but has not organized and documented it properly may find that the due diligence process creates unnecessary friction, raises avoidable concerns, or — in the worst case — surfaces problems that derail a transaction entirely. The best time to prepare for IP due diligence is not when a deal is imminent but continuously, from the earliest days of the company’s existence, so that when the moment arrives the company can respond with confidence and speed.

The Data Room: Your IP in One Place

The practical centerpiece of any due diligence process is the data room — a secure, organized repository of documents that the company makes available to the reviewing party under a confidentiality agreement. In the modern context, data rooms are almost universally virtual, hosted on secure platforms that allow controlled access, document-level permissions, and activity tracking. The quality of a startup’s data room sends an immediate signal to the reviewing party: a well-organized, comprehensive, and clearly labeled data room conveys that the company is professionally managed and has nothing to hide, while a disorganized or incomplete one raises questions before a single document has been read. For the IP component of a data room, the goal is to present a complete and coherent picture of the company’s IP estate — every patent, application, trademark, and trade secret protection measure — in a format that allows a sophisticated reviewer to quickly understand what the company owns, what it has licensed in or out, and whether the chain of title to its core assets is clean and unencumbered. Organizing the data room around clear categories, with consistent naming conventions and logical folder structures, is a worthwhile investment of time that pays dividends when a transaction is moving quickly and every day of delay has a cost.

Patents and Patent Applications

The patent component of the data room will typically receive the most scrutiny in a life sciences due diligence, and it should be organized to allow reviewers to efficiently assess both the breadth and the strength of the portfolio. For each patent and pending application, the data room can include the full prosecution history — all filings, office actions, responses, and correspondence with the patent office — as well as the current status, the countries in which protection has been sought, the expiration date or expected expiration date, and any maintenance or annuity fees that are due or overdue. Investors and their counsel will assess whether the claims of granted patents are broad enough to provide meaningful commercial protection, whether pending applications are likely to result in grants on commercially useful claims, and whether there are gaps in geographic coverage that a competitor could exploit. They will also look for any inter partes review proceedings, oppositions, or litigation involving portfolio patents, as these are indicators of both the patents’ perceived value — competitors rarely challenge patents that do not matter — and of potential vulnerabilities in the portfolio. A startup should be prepared to explain its prosecution strategy, the rationale for the countries in which it has filed, and any office actions or rejections that remain outstanding.

Assignments: Establishing Clean Chain of Title

One of the most common and consequential problems that IP due diligence uncovers is a defect in the chain of title, which is the documented sequence of transfers that establishes how ownership of a patent moved from the individual inventors to the company. As discussed in the inventorship section, inventors own their inventions by default, and ownership transfers to the company only through a written assignment. In due diligence, reviewers will trace the chain of title for every material patent and application, verifying that a properly executed assignment exists from each named inventor to the company, and that each assignment has been recorded with the USPTO or the relevant foreign patent office. Unrecorded assignments, missing signatures, assignments executed after the fact, or gaps arising from inventors who left the company before signing can all raise serious concerns about whether the startup truly owns what it claims to own. Startups should audit their assignment records proactively — ideally well before any transaction is contemplated — and address any gaps with the assistance of patent counsel. Correcting an assignment defect is almost always possible when there is time and goodwill to do so; discovering the same defect in the middle of a time-sensitive transaction is a far more stressful and potentially costly problem to solve.

Licenses: What You Have Given and What You Have Received

The due diligence review will also examine every license agreement to which the company is a party, both as licensor and as licensee. On the inbound side — licenses the startup has received from others — reviewers will want to understand what rights have been granted, whether those rights are exclusive or non-exclusive, what field of use and geographic restrictions apply, what financial obligations attach to the license including upfront fees, milestones, and royalties, and whether the license is sublicensable to partners or acquirers. This last point is particularly important in acquisition scenarios: if a startup’s core technology is built on a license from a university or research institution, the acquirer needs to know whether that license will survive the acquisition or whether it contains change-of-control provisions that could cause it to terminate or require renegotiation. On the outbound side — licenses the startup has granted to others — reviewers will assess whether any existing licenses limit the company’s freedom to commercialize its technology or grant rights that could conflict with the interests of an incoming investor or acquirer. Any license that grants exclusivity in a commercially significant field or territory deserves particular attention and clear explanation.

Other Agreements That Affect IP

Beyond formal license agreements, due diligence will surface a range of other agreements that can have significant bearing on the company’s IP position. Sponsored research agreements with universities or other institutions may contain provisions granting the institution rights to inventions arising from the funded research or giving the startup a right of first negotiation to license resulting IP — terms that need to be understood and disclosed. Collaboration and co-development agreements with industry partners may create jointly owned IP, with all of the complications that joint ownership entails as described earlier in this booklet. Material transfer agreements governing the use of biological materials, cell lines, or compounds provided by third parties may impose restrictions on how inventions arising from use of those materials can be patented or commercialized. Confidentiality and non-disclosure agreements are relevant to the extent they govern disclosures that could affect the novelty of pending patent applications. Employment agreements, consulting agreements, and contractor agreements will be reviewed to confirm that invention assignment obligations are properly documented for every person who contributed to the company’s technology. Each of these agreement types represents a potential complexity that a well-prepared startup should be able to address clearly and completely.

What Investors and Acquirers Expect to See

Sophisticated life sciences investors and acquirers approach IP due diligence with a clear set of expectations and understanding those expectations allows a startup to prepare accordingly. At the most fundamental level, they expect to see that the company owns — cleanly and without encumbrance — the core IP that underlies its lead programs and products. They expect to see a patent portfolio that is strategically constructed, with claims broad enough to provide real commercial protection and geographic coverage appropriate to the company’s target markets. They expect all assignments to be properly executed and recorded, all licenses to be clearly documented with terms that are understood and manageable, and all agreements affecting IP to be organized and accessible. They will look for evidence that the company has conducted FTO analysis on its lead products, that it has a coherent prosecution strategy managed by competent outside counsel, and that it has addressed any known IP risks thoughtfully rather than hoping they will not be noticed. Perhaps most importantly, they expect the founding team to be able to speak knowledgeably and confidently about the company’s IP position — not necessarily with the depth of a patent attorney, but with sufficient understanding to demonstrate that IP has been treated as the strategic asset it is, rather than as an afterthought. A startup that meets these expectations does not merely survive due diligence; it uses the process as an opportunity to reinforce investor confidence and accelerate the path to closing.

This article is part of our Life Sciences Startup IP Resource Center.